Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Protein Manufacturing
Overview

 

Catalog Products
Online Store
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
Ranked #1 CRO1

Preclinical Services

Contact Us

ENGINEERED for the Scientific Race

Preclinical think-tank

Overview

Coalition of industry leading experts

Together with its carefully crafted network of preclinical specialists, IPA is uniquely equipped to address the complex challenges of antibody discovery projects. We are a veritable think-tank of the industry’s leading experts. We explore beyond the status-quo to deliver preclinical antibody candidates and give you the edge — with single-source services.

Services

Preclinical Services at IPA

Preclinical Services with Eurofins

Enhanced capacity from end-to-end from target evaluation through preclinical development…

Hybrid Service Model

Distinctive end-to-end service model designed to reduce time and risk with custom technologies and applications…


Breadth and Depth

Driven to provide capacity, breadth of offerings, and unique platforms…

The HUB of Biotherapeutic Intelligence: redefining end-to-end.

Highly specialized, full-continuum therapeutic biologics discovery and development to support pharmaceutical business partners in their quest for innovative novel biologics against the most challenging targets.

Contact Us

IPA Preclinical Services

Network of experts

Preclinical Services with Eurofins

Our notable partnership with industry leading Eurofins Discovery means access to an expanded network of experts on a global scale. It enhances our capacity for single-source efficiencies and as an “end-to-end” service provider— from target evaluation through preclinical development.

Reduce time and risk

Hybrid Service Model

Our hybrid of intelligence and technology platforms provide a distinctive end-to-end service model, designed to reduce time and risk with custom applications. We support our business partners in the quest to discover and develop novel antibodies against a broad range of classes of disease targets in “one-stop”, with: 

  • An unrivaled suite of services
  • Target design and antigen modeling
  • A broad range of immunization technologies in a multitude of species and strains
  • Best-in-class hybridoma, B-cell, and phage display antibody discovery platforms
  • Antibody characterization, engineering, and manufacturing services 

Distinctive platforms

Breadth and Depth

Our mission is to provide capacity, breadth of offerings, and unique platforms that accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. 

Our global network and partnership with Eurofins Discovery lends to:

  • Preclinical readiness
  • Early development stage of assets
  • Access to proprietary platforms
  • Bioanalytical solutions 
  • In vivo efficiency studies
  • Drug and product formulations
  • QC testing and batch release
  • Assay-Ready Kits and cell lines with DiscoverX, from Eurofins
Flag France

 

Eligible French companies involved with us in research and development may receive a tax credit. Learn More.

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118

In silico, in parallel, in an instant

LENSai Integrated Intelligence Technology

Tell Me More

Connect with IPA
Connect with us to solve your greatest biotherapeutic needs